Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Van de Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van de Werf, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


New aspects of pharmacological reperfusion: from macro- to microlysis

F. Van de Werf1

Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium

1 Correspondence: Frans Van de Werf, MD, Chairman, Department of Cardiology, U.Z. Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

Abstract

Recanalization of the occluded infarct-related coronary artery limits infarct size and reduces morbidity and mortality of patients with ST-segment elevation acute coronary syndromes. While of crucial prognostic significance, early patency of the infarct-related coronary artery does not tell the entire story: patency must be maintained to alter prognosis; patency of the epicardial infarct vessel does not equal re-establishment of myocardial tissue perfusion; and even late patency may be beneficial through other mechanisms that depend less on time and myocardial salvage, such as prevention of infarct expansion and left ventricular dilatation, and improvement of electrical stability. New promising strategies that may improve patency of both the epicardial coronary artery (macrolysis) and the distal vasculature (microlysis) are being evaluated. Of particular interest is the combined use of glycoprotein IIb/IIIa receptor antagonists and reduced dose fibrinolytics. This combination is currently being tested in three angiographic trials (FASTER, INTEGRITI, ENTIRE) and in two large trials with clinical end-points (GUSTO-V and ASSENT-3). Furthermore, new promising agents that can limit ischaemia reperfusion injury have entered the clinical testing phase. It is likely that these new strategies will further improve the efficacy of pharmacological reperfusion.

Key Words: pharmacological perfusion • microlysis • macrolysis

References

  1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902[Abstract]
  2. Davies MJ, Thomas AC. Plaque fissuring — the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363–373[Free Full Text]
  3. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786–794[Abstract/Free Full Text]
  4. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]
  5. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TEMI) Trial: Phase I findings. N Engl J Med. 1985;312:932–936[Medline]
  6. Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction]. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985;1:842–847[Web of Science][Medline]
  7. International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with and without heparin. Lancet. 1990;336:71–75[CrossRef][Web of Science][Medline]
  8. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753–770[Web of Science][Medline]
  9. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622[Abstract/Free Full Text]
  10. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989;14:1566–1569[Abstract]
  11. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412–1417[CrossRef][Web of Science][Medline]
  12. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142–154[Abstract/Free Full Text]
  13. Anderson JL, Karagounis LA, Califf RM. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol. 1996;78:1–8[Web of Science][Medline]
  14. Simes RJ, Topol EL, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923–1928[Abstract/Free Full Text]
  15. Reiner IS, Lundergan CF, Rohrbeck SC, et al. The impact on left ventricular function of coronary reocclusion after successful thrombolysis for acute myocardial infarction. J Am Coll Cardiol. 1994;23:13A
  16. Brouwer MA, B'hncke JR, Veen G, Meijer A, Van Eenige ML, Verheugt FWA. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol. 1995;26:1440–1444[Abstract]
  17. White HD, French JK, Hamer AW, et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol. 1995;25:218–223[Abstract]
  18. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 1994;74:1220–1228[CrossRef][Web of Science][Medline]
  19. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311–322[CrossRef][Web of Science][Medline]
  20. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771–775[CrossRef][Web of Science][Medline]
  21. Clemmensen P, Ohman EM, Sevilla DC, et al. Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. Am J Cardiol. 1992;70:1391–1396[CrossRef][Web of Science][Medline]
  22. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarc-trelated artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993;21:1391–1395[Abstract]
  23. Kennedy JW. Optimal management of acute myocardial infarction requires early and complete reperfusion. Circulation. 1995;91:1905–1907[Free Full Text]
  24. Lenderink T, Simoons ML, Van Es GA, et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 1995;92:1110–1116[Abstract/Free Full Text]
  25. Reiner JS, Lundergan CF, Fung A, et al. Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation. 1996;94:2441–2446[Abstract/Free Full Text]
  26. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–888[Abstract/Free Full Text]
  27. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation. 1998;99:1945–1950
  28. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1989;1:1367–1369[Web of Science][Medline]
  29. Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation. 1993;88:2426–2436[Free Full Text]
  30. Nash J. The open infarct-related artery: theoretical and practical considerations. Cor Art Dis. 1995;6:739–749
  31. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival. Should the paradigm be expanded? Circulation. 1989;79:441–444[Free Full Text]
  32. Califf RM, Topol EL, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol. 1989;14:1382–1388[CrossRef][Web of Science][Medline]
  33. Gang ES, Lew AS, Hong M, Wang FZ, Siebert CA, Peter T. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1989;321:712–716[Abstract]
  34. Sager PT, Perlmutter RA, Rosenfeld LE, McPherson CA, Wackers FL, Batsford WP. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol. 1988;12:19–24[Abstract]
  35. Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987;75:299–306[Abstract/Free Full Text]
  36. Lavie CJ, O'Keefe JH Jr, Chesebro JH, Clements IP, Gibbons RJ. Prevention of late ventricular dilatation after acute myocardial infarction by successful thrombolytic reperfusion. Am J Cardiol. 1990;66:31–36[CrossRef][Web of Science][Medline]
  37. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–1172[Abstract/Free Full Text]
  38. White HD, Cross DB, Elliot JM, Norris RM, Yee TW. Long term prognostic importance of patency of the infarct related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994;89:61–67[Abstract/Free Full Text]
  39. Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation. 1995;92:1101–1109[Abstract/Free Full Text]
  40. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;88:1361–1374[Abstract/Free Full Text]
  41. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85:1699–1705[Abstract/Free Full Text]
  42. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93:1993–1999[Abstract/Free Full Text]
  43. Maes A, Van de Werf F, Nuyts J, Bormans G, Desmet W, Mortelmans L. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. Circulation. 1995;92:2072–2078[Abstract/Free Full Text]
  44. Schröder R, Wegscheider K, alSchröder K, Dissmann R, Meyer-Sabellek W. Extent of early ST-segment elevation resolution: a strong prediction of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. J Am Coll Cardiol. 1995;26:1657–1664[Abstract]
  45. Kawamoto T, Yoshida K, Akasada T, et al. Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angiography predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation. 1999;100:339–345[Abstract/Free Full Text]
  46. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acuue myocardial infarction. Circulation. 1998;97:765–772[Abstract/Free Full Text]
  47. Gibson MC, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality following thrombolytic administration (in press).
  48. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114–3124[Free Full Text]
  49. Verstraete M, Lijnen HR, Collen D. Thrombolytic agents in development. Drugs. 1995;50:29–42[Web of Science][Medline]
  50. White HD, Van de Werf F. Thrombolysis for acute myocardial infarction. Circulation. 1998;97:1632–1646[Abstract/Free Full Text]
  51. Van de Werf F. New fibrinolytics. Textbook of Cardiovascular Medicine Updates. 1999;vol 2:1–11
  52. ASSENT-2 investigators. Single-bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet. 1999;354:716–722[CrossRef][Web of Science][Medline]
  53. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs. 1995;49:856–884[Web of Science][Medline]
  54. Weitz JI, Califf RM, Ginsberg JS, Hirsch J, Théroux P. New antithrombotics. Chest. 1995;108:471S–485S[Free Full Text]
  55. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J. 1996;17:9–18[Free Full Text]
  56. Amman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]
  57. The SPEED group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;101:2788–2794[Abstract/Free Full Text]
  58. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J. 2000;21:1944–1953[Abstract/Free Full Text]
  59. Brener SL, Adgey JA, Zeymer U, Strony JS, Topol EJ. Combination low dose t-PA and eptifibatide for acute myocardial infarction. Final results of the Intro-AMI Study. Circulation. 2000;102:II–599
  60. Brener SJ, Barr LA, Burchenal IF, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction (RAPPORT). Circulation. 1998;98:734–741[Abstract/Free Full Text]
  61. Montalescot G, Barragan P, Wittenberg O, et al. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: the ADMIRAL study, 30-day final results. Circulation. 1999;100:I–87
  62. Stone GW. The CADILLAC trial. Final results presented at the Scientific Sessions 2000 of the AHA in New Orleans. November 2000.
  63. Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide dismutose (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angi oplasty for acute myocardial infarction. Circulation. 1994;89:1982–1991[Abstract/Free Full Text]
  64. Wall T, Califf R, Blakenship J, et al. Intravenous Fluosol in the treatment of acute myocardial infarction: results of the TAMI-9 trial. Circulation. 1994;90:114–120[Abstract/Free Full Text]
  65. Gourlay S. LIMIT-AMI: angiographic safety and efficacy trial of a novel anti-CD 18 therapy in acute myocardial infarction in conjunction with thrombolysis. Amsterdam, The NetherlandsPresented at the XXII Congress of the European Society of Cardiology. August 2000.
  66. Kumar A, Villani MP, Patel UK, Keith JC, Schaub RG. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation. 1999;99:1363–1369[Abstract/Free Full Text]
  67. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Circulation. 1998;97:2259–2267[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Van de Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van de Werf, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?